In late October, representatives of NANOLEK - Maxim Kurbatov, Head of the Department of Market Launch of Medicines, and Vadim Kalinichenko, Head of the Medical Department, took part in the round table discussion “Early diagnosis and multidisciplinary approach are the key to high quality of life for patients with mucopolysaccharidosis (MPS II)”.
The discussion held in Almaty (Kazakhstan) was organized by the Scientific center of pediatrics and pediatric surgery under the Ministry of health of the Republic of Kazakhstan.
The main objective of the event was to share experience in the area of orphan pathology (MPS II), experience on enzyme replacement therapy with physicians and patient organizations as well as to provide assistance to patients and their parents. Special attention was paid to analyzing the characteristics of Hunterase® (previously, a market authorization was issued by the Ministry of health of the Republic of Kazakhstan).
Vadim Kalinichenko spoke about the importance of early diagnosis and a multidisciplinary approach in the diagnosis of MPS II, and Maxim Kurbatov covered the issues of social adaptation and rehabilitation support for patients with MPS II.
NANOLEK positions itself as a socially responsible company that has drugs in its portfolio to treat orphan diseases, in particular MPS II. This is a severe disabling disease that manifests itself in early childhood and leads to death without proper treatment. Therefore, it is crucial to recognize the symptoms of the disease as early as possible. The only possible method of pathogenetic therapy for patients with MPS II today is enzyme replacement therapy.
Vadim Kalinichenko answered in detail the questions asked by physicians present at the meeting concerning the effectiveness and safety of idursulfase beta, its advantages as compared to the therapy used. Maxim Kurbatov went into details concerning the experience of providing assistance from the time of diagnosis to prescribing treatment with enzyme replacement drug Hunterase®.
The discussion also included exchange of contacts between laboratories of
Republican centers in order to establish working relations, talks about the
ways of assistance by NANOLEK at the stages of MPS II screening and diagnosis
in the Republic of Kazakhstan, and talks about possible ways of involvement of
physicians of Republican centers dealing with treatment of patients with orphan
pathologies in clinical trials.
Experts of NANOLEK took part in the round table discussion “Early diagnosis and multidisciplinary approach are the key to high quality of life for patients with mucopolysaccharidosis”
